X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare JUBILANT LIFE SCIENCES with Sun Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs SUN PHARMA - Comparison Results

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT LIFE SCIENCES SUN PHARMA JUBILANT LIFE SCIENCES/
SUN PHARMA
 
P/E (TTM) x 29.2 23.6 123.6% View Chart
P/BV x 6.0 3.4 173.6% View Chart
Dividend Yield % 0.3 0.7 45.6%  

Financials

 JUBILANT LIFE SCIENCES   SUN PHARMA
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-14
SUN PHARMA
Mar-17
JUBILANT LIFE SCIENCES/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs187842 22.2%   
Low Rs65572 11.4%   
Sales per share (Unadj.) Rs364.3131.6 276.8%  
Earnings per share (Unadj.) Rs6.832.7 20.9%  
Cash flow per share (Unadj.) Rs24.538.0 64.5%  
Dividends per share (Unadj.) Rs3.003.50 85.7%  
Dividend yield (eoy) %2.40.5 481.3%  
Book value per share (Unadj.) Rs164.9152.7 108.0%  
Shares outstanding (eoy) m159.282,399.26 6.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.35.4 6.4%   
Avg P/E ratio x18.421.6 85.1%  
P/CF ratio (eoy) x5.118.6 27.6%  
Price / Book Value ratio x0.84.6 16.5%  
Dividend payout %43.810.7 409.5%   
Avg Mkt Cap Rs m20,0611,696,877 1.2%   
No. of employees `0006.217.5 35.3%   
Total wages/salary Rs m11,05249,023 22.5%   
Avg. sales/employee Rs Th9,383.018,028.3 52.0%   
Avg. wages/employee Rs Th1,786.92,798.8 63.8%   
Avg. net profit/employee Rs Th176.34,479.5 3.9%   
INCOME DATA
Net Sales Rs m58,034315,784 18.4%  
Other income Rs m1916,232 3.1%   
Total revenues Rs m58,224322,016 18.1%   
Gross profit Rs m5,786100,893 5.7%  
Depreciation Rs m2,81212,648 22.2%   
Interest Rs m3,2373,998 81.0%   
Profit before tax Rs m-7290,479 -0.1%   
Minority Interest Rs m-2860-   
Prior Period Items Rs m099 0.0%   
Extraordinary Inc (Exp) Rs m2,1450-   
Tax Rs m69612,116 5.7%   
Profit after tax Rs m1,09078,462 1.4%  
Gross profit margin %10.031.9 31.2%  
Effective tax rate %-965.913.4 -7,213.1%   
Net profit margin %1.924.8 7.6%  
BALANCE SHEET DATA
Current assets Rs m29,280329,537 8.9%   
Current liabilities Rs m38,912178,870 21.8%   
Net working cap to sales %-16.647.7 -34.8%  
Current ratio x0.81.8 40.8%  
Inventory Days Days8479 106.8%  
Debtors Days Days5183 60.9%  
Net fixed assets Rs m55,712204,766 27.2%   
Share capital Rs m1552,399 6.4%   
"Free" reserves Rs m20,968363,997 5.8%   
Net worth Rs m26,265366,397 7.2%   
Long term debt Rs m17,16914,361 119.6%   
Total assets Rs m88,606614,102 14.4%  
Interest coverage x1.023.6 4.1%   
Debt to equity ratio x0.70 1,667.8%  
Sales to assets ratio x0.70.5 127.4%   
Return on assets %4.913.4 36.4%  
Return on equity %4.221.4 19.4%  
Return on capital %11.624.8 46.6%  
Exports to sales %37.80-   
Imports to sales %16.50-   
Exports (fob) Rs m21,933NA-   
Imports (cif) Rs m9,567NA-   
Fx inflow Rs m22,00444,118 49.9%   
Fx outflow Rs m11,74924,484 48.0%   
Net fx Rs m10,25519,634 52.2%   
CASH FLOW
From Operations Rs m8,02670,822 11.3%  
From Investments Rs m-1,744-42,216 4.1%  
From Financial Activity Rs m-4,447-22,854 19.5%  
Net Cashflow Rs m1,8346,107 30.0%  

Share Holding

Indian Promoters % 45.6 63.7 71.6%  
Foreign collaborators % 3.5 0.0 -  
Indian inst/Mut Fund % 8.7 5.1 169.6%  
FIIs % 21.2 23.0 92.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.1 8.3 254.2%  
Shareholders   23,815 133,026 17.9%  
Pledged promoter(s) holding % 15.9 0.5 2,990.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT LIFE SCIENCES With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  FULFORD INDIA  ALEMBIC PHARMA  ELDER PHARMA  

Compare JUBILANT LIFE SCIENCES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Firm; Software & FMCG Stocks Gain(Closing)

Indian share markets finished the trading session well above the dotted line, snapping a three-day falling streak amid firm Asian markets.

Related Views on News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

Dec 12, 2016

Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Feb 21, 2018 (Close)

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES - BIOCON LTD COMPARISON

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS